股票简称：保龄宝 股票代码：002286 公告编号：2025-034 保龄宝生物股份有限公司 关于选举职工代表董事的公告 保龄宝生物股份有限公司董事会 2025 年 5 月 20 日 附：个人简历 杨雪，女，1988 年出生，研究生学历；2018 年 3 月起先后担任保龄宝国际 有限公司总经理助理、人事行政部主管、董事。2024 年 4 月至 2025 年 5 月任公 司职工代表监事、监事会主席。2025 年 5 月起任公司职工代表董事。 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 根据《公司法》《公司章程》等有关规定，保龄宝生物股份有限公司（以下 简称"公司"）于2025年5月20日召开第六届职工代表大会第四次会议，经全体 与会职工代表一致同意，选举杨雪女士（个人简历附后）为公司职工代表董事。 公司董事会中兼任公司高级管理人员以及由职工代表担任的董事人数总计 不超过公司董事总数的二分之一。 本次会议的召集、召开和表决程序符合《公司法》《公司章程》等有关规 定。上述职工代表董事符合《公司法》等法律法规中有关董事任职的资格和条 件。 特此公告。 截至目前，杨雪女 ...

证券代码：002286 证券简称：保龄宝 公告编号：2025-033 保龄宝生物股份有限公司 2024 年年度股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1.本次股东会由保龄宝生物股份有限公司（以下简称"公司""保龄宝"）董事 会召集。召开本次股东会的通知已于 2025 年 4 月 25 日在公司指定信息披露媒体 上予以公告。所有议案已在本次股东会通知公告中列明，相关议案内容已依法披 露。 2.本次股东会无否决提案的情形。 3.本次股东会不涉及变更前次股东会决议。 一、会议召开情况 （一）会议召开时间： 1.现场会议召开时间：2025 年 5 月 20 日（星期二）下午 14：00。 2.网络投票时间：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 5 月 20 日 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳证券交易所互联网 投票系统进行投票的时间为 2025 年 5 月 20 日上午 9：15 至下午 15：00。 （二）现场会议召开地点：山东省德州（禹城）国家高新技术产业开发 ...

北京雍行律师事务所 关于保龄宝生物股份有限公司 2024 年年度股东会的法律意见书 致：保龄宝生物股份有限公司 根据《中华人民共和国证券法》《中华人民共和国公司法》（以下简称"《公 司法》"）、《上市公司股东会规则》（以下简称"《股东会规则》"）、《律 师事务所从事证券法律业务管理办法》（以下简称"《证券法律业务管理办法》"） 等相关法律、法规和规范性文件以及《保龄宝生物股份有限公司章程》（以下简 称"《公司章程》"）的规定，北京雍行律师事务所（以下简称"本所"）指派 本所律师出席保龄宝生物股份有限公司（以下简称"保龄宝"）2024 年年度股东 会（以下简称"本次股东会"），并出具本法律意见书。 本所律师已经按照《股东会规则》的要求对本次股东会的真实性、合法性进 行了核查和验证（以下简称"查验"）并发表法律意见，本法律意见书中不存在 虚假记载、误导性陈述及重大遗漏，否则本所律师将承担相应的法律责任。本所 律师无法对网络投票股东资格进行核查，在参与网络投票的股东资格均符合法律、 行政法规、规范性规定及《公司章程》规定的前提下，相关出席会议股东符合资 格。 在本法律意见书中，本所及本所律师仅就本次股东会的召集和召 ...

Mergers and Acquisitions - Multiple companies are experiencing stock price increases due to merger and acquisition activities, with notable gains including Zongyi Co. at 10.10% and Daqimo at 10.06% [2][3] - New entrants in the market such as Binhai Energy and Jinhongshun also saw significant increases of 10.00% and 9.98% respectively, attributed to similar merger activities [2] - The trend continues with companies like Huayuan Real Estate and Hunan Development achieving first board listings with gains of 9.94% and 9.97% [3] Shipping and Ports - Following the implementation of tariff adjustments between China and the US, there has been a surge in container bookings from China to the US, positively impacting shipping and port stocks [4] - Nanjing Port, Ningbo Shipping, and Lianyungang have all recorded five consecutive days of price increases, with gains of 9.97%, 10.04%, and 10.07% respectively [4][6] Robotics - The robotics sector is gaining attention, with Nvidia's CEO indicating that all mobile devices will become robots, potentially revolutionizing the industrial sector [7] - Companies like Zhongchao Holdings and Xinlong Health have seen stock increases of 10.13% and 10.01% respectively, driven by advancements in robotics [8] Chemical Products - Recent price hikes in chemical products such as dibutyl phthalate and hydroxyl esters have drawn market attention, benefiting companies like Zhongyida and Youfu Co. with stock increases of 9.99% and 10.04% [10][11] Food and Beverage - The release of new regulations by the Ministry of Commerce and the National Development and Reform Commission is expected to boost the food and beverage sector, with stocks like Jiaoda Angli and Baihe Co. seeing gains of 10.00% and 10.01% [12][15] Military and Aerospace - The debut of the "Jiutian" drone at the 15th China Airshow is anticipated to enhance the military sector, with companies like Chengfei Integration and Lijun Co. achieving stock increases of 10.00% and 10.02% [16][19] Nuclear Power - The announcement of procurement projects by China Fusion Energy Co. is expected to stimulate the nuclear power sector, benefiting companies like Wangzi New Materials and Baili Electric with stock increases of 9.99% and 9.92% [16][17] Venture Capital - Recent regulatory changes encouraging private equity participation in mergers and acquisitions are positively impacting venture capital stocks, with companies like Jiuding Investment and Electronic City seeing gains of 10.01% and 9.90% [19] Pet Economy - The pet economy is projected to grow significantly, with companies like Yuande Pet and Tianyuan Pet achieving stock increases of 9.98% and 20.00% [20][21] Carbon Fiber - Price increases in carbon fiber products have been reported, benefiting companies like Jilin Chemical Fiber with a stock increase of 10.04% [22][23] Smart Driving - The Ministry of Industry and Information Technology's push for mandatory standards in smart connected vehicles is expected to drive growth in the automotive sector, with companies like Wan'an Technology and Luchang Technology seeing stock increases of 10.00% [26][27] Rare Earth Permanent Magnets - Tightening supply of rare earth materials due to export controls has led to price increases, benefiting companies like Huayang New Materials and Jiuwu High-Tech with stock increases of 10.10% and 20.02% [28][29] Huawei Harmony - Huawei's upcoming product launch is expected to positively impact related stocks, with companies like Dongfang Zhongke and Dahua Intelligent seeing stock increases of 10.01% and 9.94% [30]

Group 1: Product Development and Collaborations - The company is developing customized product formulations using allulose for various clients in the food and beverage sector, collaborating with numerous tea brands [3] - The company aims to lower the production costs of erythritol through process improvements and is expanding its application areas for this product [4] - The company plans to increase allulose production capacity to approximately 30,000 tons by 2026, following the initiation of a 20,000-ton expansion project in March 2025 [4] Group 2: Market Impact and Regulatory Environment - The company benefits from a 3.29% anti-subsidy tax rate on erythritol, which is the lowest among related companies, potentially aiding product exports [4] - The overall impact of tariff policies on the company's operations is limited, with normal production and business conditions reported [5] Group 3: Future Outlook and Strategic Initiatives - There is a growing demand for sugar-free and health-oriented products due to rising income levels and changing consumer preferences, which the company aims to capitalize on [5] - The company is focused on improving operational efficiency through lean management, flexible production, and market channel expansion to enhance profitability [5]

证券代码：002286 证券简称：保龄宝 公告编号：2025-032 保龄宝生物股份有限公司董事会薪酬与考核委员会 关于2025年限制性股票激励计划 首次授予激励对象名单的核查意见及公示情况说明 本公司及董事会薪酬与考核委员会全体成员保证信息披露内容的真实、准 确和完整，没有虚假记载、误导性陈述或重大遗漏 保龄宝生物股份有限公司（以下简称"公司"）于2025年4月24日召开了第六 届董事会第九次会议，审议通过了《关于 <保龄宝生物股份有限公司2025年限制> 性股票激励计划（草案）>及其摘要的议案》等议案。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司股 权激励管理办法》（以下简称"《管理办法》"）等法律、法规及规范性文件和 《保龄宝生物股份有限公司章程》（以下简称"《公司章程》"）的规定，公司 对2025年限制性股票激励计划（以下简称"本激励计划"）首次授予激励对象的 姓名和职务在公司内部进行了公示。公司董事会薪酬与考核委员会结合公示情 况对激励对象相关信息进行了核查，相关公示情况及核查意见如下： 司章程》等法律、法规和规范性文件规定的激励对象条件，符合《激励计划 （草案）》规定的激励对 ...

证券代码：002286 证券简称：保龄宝 公告编号：2025-032 保龄宝生物股份有限公司董事会薪酬与考核委员会 关于2025年限制性股票激励计划 首次授予激励对象名单的核查意见及公示情况说明 本公司及董事会薪酬与考核委员会全体成员保证信息披露内容的真实、准 确和完整，没有虚假记载、误导性陈述或重大遗漏 保龄宝生物股份有限公司（以下简称"公司"）于2025年4月24日召开了第六 届董事会第九次会议，审议通过了《关于<保龄宝生物股份有限公司2025年限制 性股票激励计划（草案）>及其摘要的议案》等议案。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《上市公司股 权激励管理办法》（以下简称"《管理办法》"）等法律、法规及规范性文件和 《保龄宝生物股份有限公司章程》（以下简称"《公司章程》"）的规定，公司 对2025年限制性股票激励计划（以下简称"本激励计划"）首次授予激励对象的 姓名和职务在公司内部进行了公示。公司董事会薪酬与考核委员会结合公示情 况对激励对象相关信息进行了核查，相关公示情况及核查意见如下： 一、公示情况及核查方式 1、公司于2025年4月25日于巨潮资讯网（www.cninfo.co ...

Core Viewpoint - The U.S. Department of Commerce has made a preliminary ruling on countervailing duties for erythritol imported from China, impacting companies like Baolingbao and Sanyuan Biotech, which are adjusting their strategies in response to the investigation [1][2]. Company Responses - Sanyuan Biotech has acknowledged the impact of the U.S. investigation on its sales and is shifting its sales strategy to focus more on the domestic health consumer market while also exploring new markets in Southeast Asia, India, and the Middle East [1][3]. - Baolingbao, facing a lower anti-dumping tax rate of 34.4% from the EU, has seen a significant increase in revenue from erythritol products in Europe, with a 123% year-on-year growth in Q1 2025 [3]. Industry Challenges - The sugar substitute industry is facing multiple international trade challenges, including anti-dumping investigations from both the U.S. and the EU, with the EU imposing anti-dumping duties ranging from 34.4% to 233.3% [2][3]. - The domestic erythritol market is currently experiencing low prices, but the competitive landscape is easing, which may lead to a more stable supply-demand balance in the future [4]. Financial Performance - In 2024, Sanyuan Biotech reported revenues of 710 million yuan, a 42.7% increase year-on-year, and a net profit of 110 million yuan, up 87.5% [3]. - Baolingbao's revenue for the same period was 2.4 billion yuan, a decrease of 4.8%, but its net profit increased by 106% to 110 million yuan [3].

智通财经5月14日电，美国商务部发布公告，对进口自中国的赤藓糖醇（Erythritol）作出反补贴初裁， 初步裁定保龄宝生物股份有限公司（Baolingbao Biology Co., Ltd.）税率为3.29%、山东三元生物科技股 份有限公司（Shandong Sanyuan Biotechnology Co., Ltd. ）税率为3.49%，中国其他生产商/出口商的税率 为3.47%。2025年1月2日，美国商务部宣布对进口自中国的赤藓糖醇发起反倾销和反补贴调查。 美国作出赤藓糖醇反补贴初裁 ...

Market Outlook - The market for health-conscious products is expected to grow significantly due to rising income levels and changing consumer preferences towards sugar-free and nutritious options [2] - The aging population presents a substantial opportunity in the silver economy, with increasing demand for health improvement products [2] - National policies are anticipated to further boost the market for natural sweeteners and functional health foods such as prebiotics and dietary fibers [2] Revenue Projections - The company aims for a net profit of no less than 170 million RMB in 2025 as part of its stock incentive plan [6] - The company expects stable growth in its three core products: prebiotics, dietary fibers, and sugar-reducing sweeteners [4] Production Capacity - The company has initiated a project to expand its production capacity of allulose to 20,000 tons annually, with an expected total capacity of approximately 30,000 tons by 2026 [3] - The company has completed the construction of a 2,500-ton annual production line for HMOs (human milk oligosaccharides) and is currently in the trial production phase [6] Impact of Raw Material Prices - The company is closely monitoring corn prices and employing strategies to balance procurement costs and market uncertainties [3] Export and Market Expansion - The company plans to establish a sales subsidiary in the U.S. and enhance customer service to increase market share [7] - The company’s export business to the U.S. is expected to benefit from reduced tariffs, which will facilitate exports [4] Industry Trends - The overall industry is benefiting from the growing health consciousness among consumers and the aging population, which is driving demand for health-related products [11] - The company’s market share for erythritol in the EU has increased to 50%, with a significant revenue growth of approximately 123% year-on-year in Q1 2025 [5] Stock Performance and Investor Relations - The company is actively engaging in investor relations to improve market perception and stock performance, including hosting analyst meetings and enhancing information disclosure [10] - The company acknowledges that stock price is influenced by various factors, including company earnings and market conditions [12]